Pharmaceutical Technology1 天
Fosmanogepix by Basilea Pharmaceutica for Aspergillosis: Likelihood of Approval
Fosmanogepix is under clinical development by Basilea Pharmaceutica and currently in Phase II for Aspergillosis.
University of Manchester6 个月
Changing understanding and treatment of Aspergillus disease globally
Chronic pulmonary aspergillosis is often confused with TB and has a five-year survival rate of less than 50%. Surgery had previously been the standard treatment, but research, led by Dr David Denning, ...
University of Manchester24 年
Deadly mould strains highly likely to acquire resistance to new drugs
Scientists have identified strains of one of the world’s most dangerous fungal pathogens, already resistant to our most ...
Pharmaceutical Technology1 天
Fosmanogepix by Basilea Pharmaceutica for Unspecified Fungal Infections: Likelihood of Approval
Fosmanogepix is under clinical development by Basilea Pharmaceutica and currently in Phase II for Unspecified Fungal Infections.
News Medical29 天
Key risk factors influencing mortality rates in chronic pulmonary aspergillosis patients
CPA includes multiple lung diseases, such as chronic cavitary pulmonary aspergillosis (CCPA ... was the most frequently used first-line treatment, followed by voriconazole. Random-effects meta ...
来自MSN29 天
Common Fungal Infection Found To Be Fatal For Lung Disease Patients: AIIMS Study Reveals
While exposure to Aspergillus is harmless to most people ... and then not treated with antifungal agents. Treatment with antifungal drugs or surgery is key to improving symptoms and also reducing ...